Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

779.67 -2.71 (-0.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

49 50 Next >

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today ↗

December 23, 2024

Via Benzinga

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗

December 22, 2024

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Via Benzinga

Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study ↗

December 17, 2024

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025.

Via Benzinga

Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts ↗

December 17, 2024

Wall Street began Tuesday’s session on a weaker note, with major indices slipping after November's robust retail sales report reignited investor concerns that the Federal Reserve might hold back...

Via Benzinga

Topics Economy

What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals ↗

December 17, 2024

Via Benzinga

Regeneron Pharmaceuticals Unusual Options Activity ↗

November 26, 2024

Via Benzinga

Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗

December 16, 2024

The weight-loss drugs space continues to heat up. Here's the latest news from the segment.

Via Investor's Business Daily

Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money' ↗

December 04, 2024

Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing sales challenges.

Via Benzinga

It’s Been A Tough Month For Healthcare Stocks ↗

December 02, 2024

It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.

Via Talk Markets

Topics ETFs Stocks / Equities

Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking ↗

November 19, 2024

Via Benzinga

Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗

November 18, 2024

Via Benzinga

Check Out What Whales Are Doing With REGN ↗

November 15, 2024

Via Benzinga

28 Analysts Have This To Say About Regeneron Pharmaceuticals ↗

November 14, 2024

Via Benzinga

Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry ↗

November 06, 2024

Via Benzinga

This Is What Whales Are Betting On Regeneron Pharmaceuticals ↗

November 04, 2024

Via Benzinga

Not-So-Big Pharma ↗

November 16, 2024

Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.

Via Talk Markets

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease ↗

November 15, 2024

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025.

Via Benzinga

2 Top Growth Stocks to Buy on the Dip ↗

November 14, 2024

Their recent issues are nothing to fret over for investors focused on the long game.

Via The Motley Fool

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease ↗

November 13, 2024

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

Via Benzinga

3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt

November 06, 2024

Check out these three stocks with financial metrics showing recession resistance and underlying business dynamics to back them up.

Via MarketBeat

Topics Bankruptcy Bonds Economy

Regeneron Earnings Top Views For Biotech Giant ↗

October 31, 2024

Shares of the biotech giant have been in a sharp slide.

Via Investor's Business Daily

Is It Time to Buy October's Worst-Performing Nasdaq Stocks? ↗

November 06, 2024

Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.

Via The Motley Fool

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say ↗

November 05, 2024

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.

Via Benzinga

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗

November 04, 2024

A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.

Via Talk Markets

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? ↗

October 31, 2024

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.

Via Benzinga

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss ↗

October 28, 2024

EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients.

Via Benzinga

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗

October 28, 2024

One of these players has split its stock in the past. The other one hasn't.

Via The Motley Fool

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? ↗

October 31, 2024

Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

Headline News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today